Coronavirus Disease 2019 and Vaccination of Children and Adolescents: Prospects and Challenges by Zimet, Gregory D. et al.
COVID-19 and Vaccination of Children and Adolescents: Prospects and Challenges 
Gregory D. Zimet, Phd 
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA 
Ross D. Silverman, JD, MPH 
Department of Health Policy and Management, Indiana University Richard M. Fairbanks School of Public 
Health, and Indiana University Robert H. McKinney School of Law, Indianapolis, IN, USA 
J. Dennis Fortenberry, MD, MS
Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA
Correspondence: Gregory D. Zimet, PhD, Division of Adolescent Medicine, Department of Pediatrics, 
Indiana University School of Medicine, 410 W. 10
th
 Street, HS 1001, Indianapolis, IN U.S.A. 46202 
Tel: (317) 274-8812 Email: gzimet@iu.edu 
Keywords: Immunization; SARS-CoV-2; Vaccine confidence; Vaccine hesitancy 
Conflict of Interest Disclosures: 
G.Z. has received consulting fees from Sanofi, Merck, and Moderna and has also received research 
support from Merck through Indiana University. The other authors declare no conflicts of interest.  
Abbreviations: 
COVID-19, Coronavirus disease 2019 
NPI, Non-pharmaceutical interventions 
SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2019 
FDA, Food and Drug Administration 
CDC, Centers for Disease Control and Prevention 
ACIP, Advisory Committee on Immunization Practices 
NASEM, National Academies of Sciences Engineering and Medicine 
HPV, Human papillomavirus 
HIV, Human immunodeficiency virus 
_______________________________________________
This is the author's manuscript of the article published in final edited form as:
Zimet, G. D., Silverman, R. D., & Fortenberry, J. D. (2021). Coronavirus disease 2019 and vaccination of children and 
adolescents: prospects and challenges. The Journal of pediatrics, 231, 254-258. https://doi.org/10.1016/j.jpeds.2020.11.002
2 
 
The ongoing coronavirus disease 2019 (COVID-19) pandemic has caused over 1,000,000 deaths 
worldwide and over 200,000 deaths in the U.S to date.
1
 Most, but not all of the deaths and more severe 
consequences of COVID-19 have been among older individuals.
2
 However, in addition to the direct 
morbidity and mortality figures, there have been enormous disruptions in the lives of persons of all 
ages, with attendant emotional, economic, and social stresses.
3, 4
 Approaches to managing the pandemic 
have relied upon what are referred to as non-pharmaceutical interventions (NPI), such as social 
distancing, wearing masks, washing hands, and testing and contact tracing. These approaches can be 
effective at mitigating the damage caused by COVID-19, but only if they are widely accepted and 
implemented, which has generally not been the case in the U.S. NPI often are characterized as stop-gap 
measures, “until a vaccine or cure is available.” In fact, there have been unprecedented efforts to 
develop vaccines to prevent infection due to the severe acute respiratory syndrome coronavirus (SARS-
CoV-2), the virus that causes COVID-19. As of the writing of this paper (October 2020), there were 44 
candidate vaccines in human clinical trials, with 11 in phase 3 trials.
5
 As a result, there is great 
expectation that a vaccine soon will be available. However, vaccination, like NPI, will not be effective 
without well-designed public health policies, clear public health communication, and widespread 
acceptance among the population. Also, we do not yet know how efficacious a vaccine will be or how 
long vaccine-induced immunity will last, including whether vaccination will need to be on a seasonal 
basis, like influenza vaccination. In addition, it is essential that a plan is in place for equitable allocation 
of any vaccine that becomes available, including for children and adolescents, to ensure that all are 
protected and that existing COVID-19 health disparities are not made worse.
6
  
There are two steps to bringing any vaccine to use in the U.S, ie, licensure and 
recommendations for use. The first is the purview of the U.S. Food and Drug Administration (FDA) and 
the second is that of the Centers for Disease Control and Prevention (CDC).  In the case of a SARS-CoV-2 
vaccine that is found to be immunogenic, safe and efficacious in phase 3 trials, and considering the 
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urgent need for a lifesaving vaccine, the FDA first might give emergency use authorization (EUA), with 
licensure pending later results of additional requested/required data.  Following EUA and/or licensure, 
the CDC, through the Advisory Committee on Immunization Practices (ACIP), considers the specifics of 
the vaccine's performance in trials, burden of disease and public health issues to recommend the 
specifics of the vaccine's use in the U.S. population and prioritization.  
 In this commentary, we address the prospects of a SARS-CoV-2 vaccine for the pediatric 
population, including discussions of the rationale for vaccinating minors, the challenges involved, the 
potential impact on acceptability of other vaccines, and reasons for moderating the uncritical optimism 
that a vaccine for children or adults, by itself, will solve our COVID-19 pandemic problems. 
What is the rationale for vaccinating minor children and adolescents? 
Morbidity and mortality associated with SARS-CoV-2 infection are significantly lower in young 
children and in adolescents, and children may be less susceptible to infection.
7
 However, there have 
been reports of COVID-19 disease symptoms, some severe, and some instances of death in children and 
adolescents. As of October, 2020, the American Academy of Pediatrics reported that nearly 700,000 
child and adolescent COVID-19 cases had been reported in the U.S. (10.7% of all cases), with over 5,000 
cumulative hospitalizations and over 100 deaths.
8
 These numbers pale compared with cases, 
hospitalizations, and deaths among individuals aged 65 years and older (e.g., as of October 14, there 
were over 160,000 cumulative deaths in this age group).
2
 Therefore, vaccination of older adults has 
significantly more potential direct benefit than vaccination of children. However, there are additional 
factors to consider. 
Although most vaccines provide direct personal health benefits, the primary public health goal 
of vaccination is herd immunity. The key question, then, is: are children vectors of transmission to more 
vulnerable adults? Increasingly, the evidence suggests that infected children and adolescents can infect 
other children and adults.9-12 To protect society as a whole, including older adults, and to decrease 
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household transmission of SARS-CoV-2, it may make sense to vaccinate children and adolescents, as well 
as adults. An additional factor is that the childhood and adolescent vaccination infrastructure is very well 
developed in the U.S., so that it should be possible to integrate new SARS-CoV-2 vaccines into existing 
immunization platforms.  
The CDC, National Academies of Sciences Engineering and Medicine (NASEM), and Johns 
Hopkins Center for Health Security all consider adults working as teachers and staff in K-12 schools and 
in out-of-home childcare settings to be critical populations needed to maintain core societal functions 
and should receive prioritized access to SARS-CoV-2 vaccines when supplies are limited. None of their 
allocation frameworks considers minor children as a high priority group.
6, 13, 14
 One could argue that part 
of protecting teacher and staff working in K-12 schools would be to also prioritize vaccination of 
students. 
 When will a SARS-CoV-2 vaccine be available for children and adolescents? 
Up until mid-October, 2020, no minors had been enrolled in any SARS-CoV-2 vaccine clinical 
trials.
15
  However, some researchers and groups, including the American Academy of Pediatrics, have 
called for clinical trials with minor adolescents to begin as soon as possible.
16, 17
 In fact, one of the 
pharmaceutical companies with a candidate SARS-CoV-2 vaccine in phase 3 clinical trials with adults was 
approved by the FDA to begin enrollment of children down to age 12 years,
18
 and reportedly had 
enrolled 100 children aged 12-15 years and 200 children aged 16-17 years by the end of October 2020.
19
 
It is not clear, however, how rapidly they will be able to continue enrolling children and minor 
adolescents into this clinical trial and we are not aware of any research that has examined parental and 
child willingness to participate in SARS-CoV-2 vaccine clinical trials. Historically, the typical course of 
research would be to conclusively demonstrate efficacy and safety in adults, then do immune-bridging 
studies in younger adolescents and children, which was the approach undertaken for human 
papillomavirus (HPV) vaccine.20 The process of developing and testing SARS-CoV-2 vaccines has been 
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accelerated significantly by enacting steps simultaneously, rather than sequentially.
21
 Moreover, the 
bioethical and procedural infrastructures for ethical conduct and implementation of vaccine prevention 
trials are under-developed for minors. The process of ensuring ethical conduct of vaccine prevention 
trials for minors is complex and uncertain, particularly in the context of incomplete data about potential 
individual benefit and safety.  Lessons from trials of HPV vaccines, as well as consideration of trials for 
potential human immunodeficiency virus (HIV) vaccines,
22, 23
 provide sound basis for SARS-CoV-2 vaccine 
research. The process could be additionally supported by detailed guidance in considering topics such as 
community benefits, diverse racial/ethnic enrollment, youths’ vulnerability, preventive misconception, 




Even in the most optimistic of circumstances, if SARS-CoV-2 vaccine development and FDA’s 
EUA/licensure and ACIP’s recommendations follow the same general course as previous vaccine trials, it 
is unlikely that a large enough number of minors could be enrolled in such studies before early- to mid-
2021. In addition, getting vaccine EUA/licensure and recommendations for minors may be a lengthier 
process than for adults, and recommendations for implementation and prioritization will be complex, 
making it unlikely that a vaccine for minors would be available before 2022.  
Another issue is that vaccine trials focus on safety and efficacy in reducing the vaccinee’s 
morbidity and mortality. They do not offer insight into how the vaccine might affect infectiousness. As 
noted in the NASEM publication, Framework for Equitable Allocation of COVID-19 Vaccine, “The ongoing 
COVID-19 vaccine trials are not designed to estimate the impact of the vaccine candidates on 
transmission and evidence of the vaccines’ actual impact on transmission might not be available for 
some time after FDA approval.”( Section S-6)6 Given that the primary goal of vaccinating children and 
adolescents would be reduction in transmission of SARS-CoV-2 to older adults, determining the impact 
of candidate vaccines on infectiousness will be essential. 
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 At the core of efforts to first recruit minors into vaccine trials and hopefully participate in SARS-
CoV-2 vaccination programs lies the need to restore and expand widespread belief in the 
trustworthiness of scientific and public health authorities. Erosion of trust in these authorities’ 
perspectives on vaccination research and vaccination began well before the ongoing COVID-19 
pandemic,
26
 but has been accentuated during this pandemic.
27, 28
 Marked disparities in SARS-CoV-2 
transmission and mortality, as well as politization of public health implementation of NPI, contribute to 
the difficulties to be faced in developing and implementing policy for use of a vaccine licensed by the 
FDA (or with FDA’s EUA) and recommended by ACIP for children and adolescents. This is an important 
issue for adolescents, as many have adopted skeptical perspectives on vaccine research and vaccination, 
based in larger societal issues of pervasive racism and discrimination, medical mistrust, and systematic 
misinformation programs addressed to social media platforms widely used by young people.
29, 30
   
Do we have to wait for vaccine availability to move towards a more normal, pre-COVID-19 lifestyle? 
We currently have tools to limit the spread of SARS-CoV-2, including wearing masks, social 
distancing, handwashing, testing and tracing, and isolating those who test positive or who have had 
close contact with others who have tested positive. Although widespread, long-term implementation of 
NPI protocols during the pandemic has introduced an array of sociocultural and developmental risks for 
children and adolescents (NASEM, page 1-15),
6
 these kind of approaches appeared to be quite effective 
at protecting children from infection at summer camps in Maine,
31
 which implemented comprehensive 
NPI, compared with a summer camp in Georgia,
10
 which did not. 
One challenge is that NPI have been implemented inconsistently and have become politically 
polarized.
32
 However, there is reason to believe that the same will be true for any SARS-CoV-2 vaccine. 
Research shows that those who identify as conservative have lower intent to get a vaccine than those 
who identify as liberal.33, 34 Also, a recent Axios-Ipsos poll indicated that only 39% of adults polled would 
get a COVID-19 vaccine as soon as it is available (43% of Democrats; 33% of Republicans).35 We need 
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national and local strategies to promote both NPI and future vaccines and to overcome the significant 
attitudinal barriers, including with respect to NPI and vaccines for children. As noted by Danchin et al, 
“To build vaccine confidence in general practice, governments need to invest in understanding the 
factors that will influence COVID-19 vaccine acceptance and plan to co-design strategies with 
communities to optimise uptake when these vaccines become available” (p. 628).
36
 We also clearly need 
to implement such national and community-based strategies based in expanded understanding of 
neurocognitive development in adolescence, and in leveraging technology to promote health-serving 
behaviors such as vaccination.
37, 38
 
Effective communication about SARS-CoV-2 vaccines also is important in order to maintain 
confidence in, and acceptability of, other pediatric and adolescent vaccines. This is particularly 
important given the significant disruptions in routine childhood and adolescent vaccination delivery due 
to the COVID-19 pandemic.
39-41
 Failures to adequately explain how efficacy of SARS-CoV-2 vaccines will 
be evaluated and safety ensured, including potential limited efficacy, could result in heightened public 
hesitancy about vaccination in general. It is encouraging that a recent study found increased parental 
intent to vaccinate children against influenza due to the COVID-19 pandemic.
42
 However, we need to 
remain vigilant about the potential for public skepticism about SARS-CoV-2 vaccination to spill over to 
childhood and adolescent vaccines. 
Will vaccine availability preclude the need for NPI? 
“Until we have a vaccine, we have to rely on NPI to manage the pandemic”. This sentence, or 
ones like this, which begin many COVID-19 articles related to NPI, harken back to behavioral research on 
HIV prevention. Many research articles started with a similar sentence in reference to controlling HIV 
and other sexually transmitted infections.43 As noted in a commentary published in 2000,43 it is a 
comment that confers second class status to NPI and implies that they will no longer be needed once a 
vaccine is developed and made available.  
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However, if used properly, NPI are very effective at controlling the spread of SARS-CoV-2 – in 
fact, possibly more effective than a vaccine with modest efficacy. Also, accepting and getting vaccinated 
is, in fact, a behavior. The development and availability of a safe and sufficiently efficacious vaccine will 
not ensure vaccine impact in the real world. This is a lesson we should have learned from HPV 
vaccination in the U.S., when, over 14 years since HPV vaccine was first licensed, the rate of series 
completion among adolescents is only 54.2%.
41
 We remain far from the Healthy People 2020 goal of 
80% HPV vaccine series completion.
44
 
In addition, without clear communication about vaccine efficacy (or limitations of efficacy) and 
length of protection, there exists the potential for risk-compensation. That is, if behavioral/social (NPI) 
mitigation efforts are substantially decreased due to reduced concerns about infection once a vaccine or 
vaccines are licensed by the FDA or receive FDA’s EUA and are recommended by ACIP, and vaccines 
have only modest efficacy and/or low uptake, then vaccine availability could have the perverse 
consequence of increasing rates of SARS-CoV-2 infection.  
Similarly, the availability of a vaccine also may result in school and public authorities 
prematurely lifting NPI restrictions or reducing enforcement of such policies, again potentially leading to 
continued outbreaks of infection. Although risk-compensation is not an issue with HPV vaccination,
45
 the 
intense desire to return to pre-COVID-19 lifestyles and/or to moderate NPI-related sociocultural and 
developmental impacts suggest that risk-compensation may become an issue with SARS-CoV-2 vaccines. 
It is essential, therefore, that public health authorities and health professionals begin now to 
communicate with patients and the public in general about the likelihood that behavioral mitigation 
strategies will continue to be needed even in the context of an approved SARS-CoV-2 vaccine. 
Conclusion 
There is a strong rationale for including children and adolescents in SARS-CoV-2 vaccine clinical 
trials and for including minors as important targets for vaccination, principally to protect older adults 
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with whom they interact, and achieve potential community protection. At the same time, it is essential 
that we temper the expectations that availability of one or more SARS-CoV-2 vaccines will allow 
children, adolescents, and adults to resume a normal, pre-COVID-19 life. The many uncertainties about 
COVID-19, about the efficacy and safety of candidate vaccines, and about the duration of vaccine-
induced immunity make it particularly important that we are as clear as possible in our communications 
about COVID-19, potential vaccines, and the almost certain situation that NPI will still be needed for 
some time to come. Such clarity of communication at the national and community levels also will help to 
maintain confidence in other childhood and adolescent vaccines. The development and availability of 
SARS-CoV-2 vaccines will represent important steps in managing the COVID-19 pandemic, but they are 
likely one element in a multifaceted set of strategies that we will need to employ. 
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